Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous regulatory T-lymphocytes
- Development stage
- Phase 2
- Lead developer
- Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous regulatory T-lymphocytes (Tregs) are an investigational cell therapy being developed by Xuzhou Medical University for the treatment of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. Tregs are a specialized subset of T cells characterized by the expression of CD4, CD25, and the transcription factor FoxP3, playing a crucial role in maintaining immune tolerance and preventing autoimmunity. In this therapeutic approach, a patient's own Tregs are isolated, expanded ex vivo, and re-infused to suppress the activation and proliferation of donor-derived effector T cells that attack the recipient's tissues. This modulation of the immune environment aims to reduce the clinical severity of GVHD while ideally preserving the beneficial graft-versus-leukemia effect. The therapy is currently being evaluated in Phase 1/2a clinical trials to assess safety and efficacy across various dose levels.
- Other names
- autologous TregsRegulator T CellsRegulatory T cells
02
Targets
ADORA2A (Adenosine A₂A Receptor)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on autologous regulatory T-lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous regulatory T-lymphocytes.